The DexCom Inc. (DXCM) Given a $84.00 Price Target by Oppenheimer Holdings Inc. Analysts

The DexCom Inc. (DXCM) Given a $84.00 Price Target by Oppenheimer Holdings Inc. Analysts

DexCom Inc. (NASDAQ:DXCM) has been given a $84.00 target price by equities research analysts at Oppenheimer Holdings Inc. in a research note issued on Wednesday. The firm currently has a “hold” rating on the medical device company’s stock. Oppenheimer Holdings Inc.’s price objective would suggest a potential upside of 15.35% from the company’s current price.

A number of other analysts also recently issued reports on DXCM. Canaccord Genuity reiterated a “buy” rating and issued a $95.00 price target on shares of DexCom in a report on Wednesday, July 13th. Jefferies Group restated a “buy” rating and issued a $98.00 target price (up from $90.00) on shares of DexCom in a report on Friday, July 15th. Deutsche Bank AG boosted their target price on shares of DexCom from $90.00 to $98.00 and gave the stock a “buy” rating in a report on Friday, July 15th. Piper Jaffray Cos. restated an “overweight” rating and issued a $93.00 target price on shares of DexCom in a report on Friday, July 15th. Finally, Zacks Investment Research upgraded shares of DexCom from a “sell” rating to a “hold” rating in a report on Tuesday, July 19th. Four analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $92.07.

Shares of DexCom (NASDAQ:DXCM) traded up 0.87% during mid-day trading on Wednesday, reaching $72.82. 472,540 shares of the company’s stock traded hands. DexCom has a 12-month low of $47.92 and a 12-month high of $96.38. The stock has a 50-day moving average price of $74.17 and a 200 day moving average price of $79.91. The firm’s market capitalization is $6155.04 billion.

In other news, insider Terrance H. Gregg sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 30th. The shares were sold at an average price of $92.14, for a total value of $921,400.00. Following the completion of the sale, the insider now owns 451,486 shares of the company’s stock, valued at approximately $41,599,920.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jay S. Skyler sold 25,000 shares of the company’s stock in a transaction that occurred on Friday, September 9th. The stock was sold at an average price of $94.07, for a total transaction of $2,351,750.00. Following the completion of the sale, the director now directly owns 5,011 shares of the company’s stock, valued at approximately $471,384.77. The disclosure for this sale can be found here. 2.80% of the stock is currently owned by company insiders.

Several large investors have recently made changes to their positions in the company. BNP Paribas Arbitrage SA boosted its stake in shares of DexCom by 3,320.0% in the third quarter. BNP Paribas Arbitrage SA now owns 1,197 shares of the medical device company’s stock valued at $105,000 after buying an additional 1,162 shares during the last quarter. Bellwether Investment Group LLC acquired a new stake in shares of DexCom during the second quarter valued at $119,000. Bank of Montreal Can acquired a new stake in shares of DexCom during the second quarter valued at $134,000. Global X Management Co. LLC boosted its stake in shares of DexCom by 118.9% in the third quarter. Global X Management Co. LLC now owns 1,900 shares of the medical device company’s stock valued at $167,000 after buying an additional 1,032 shares during the last quarter. Finally, Capstone Asset Management Co. acquired a new stake in shares of DexCom during the third quarter valued at $205,000.

About DexCom

Related posts

Leave a Comment